Mirtazapine, a Noradrenergic and Specific Serotonergic Antidepressant, Attenuates Morphine Dependence and Withdrawal in Sprague-Dawley Rats

REFERENCES

• Pouletty P. Drug discovery. Nat Rev 2002; 1: 731–736
   Google Scholar
• Kreek M J, LaForge K S, Butelman E. Drug discovery. Nat Rev 2002; 1: 710–726
   Google Scholar
• Koob G F, Bloom F E. Cellular and molecular mechanisms of drug dependence. Science (Wash. DC), 1988; 242: 715–723
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Aguilar M A, Rodriguez-Arias M, Minarro J. Effect of dopamine antagonists with different receptor blockade profiles on morphine induced place preference in male mice. Behav Brain Res 2001; 121: 189–197
   PubMed Web of Science ®Google Scholar
• Olmstead M C, Franklin K B. The development of a conditioned place preference to morphine: Effects of lesions of various CNS sites. Behav Neurosci 1997; 111: 1313–1323
   PubMed Web of Science ®Google Scholar
• Wise R A. Neurobiologyof addiction. Curr Opin Neurobiol 1996; 6: 243–251
   PubMed Web of Science ®Google Scholar
• Haney M, Collins E D, Ward A S, Foltin R W, Fischman M W. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology (Berl.) 1999; 143: 102–110
   PubMed Web of Science ®Google Scholar
• Gray A M. The effect of fluvoxamine and sertraline on the opioid withdrawal syndrome: A combined in vivo cerebral microdialysis and behavioural study. European Neuropsychopharmacology 2002; 12: 245–254
   PubMed Web of Science ®Google Scholar
• Lin L, et al. Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. Life Science 2001; 69: 37–46
   PubMed Web of Science ®Google Scholar
• De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. International Clinical Psychopharmacology 1996; 10(Suppl. 4)19–23
   Google Scholar
• De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(Suppl. 4)19–25
   PubMed Web of Science ®Google Scholar
• Liappas J, et al. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005; 29: 55–60
   PubMed Web of Science ®Google Scholar
• Bomholt S F, Mikkelsen J D, Blackburn-Munro G. Antinociceptive effects of the antidepressants duloxetine, mirtazapine and citalopram in animal models of acute neuropathic pain. Neuropharmacology 2005; 48(2)252–263
   PubMed Web of Science ®Google Scholar
• Zhou Q, et al. Substance P(1–7) affects the expression of dopamine D2 receptor mRNA in male rat brain during morphine withdrawal. Peptides 2003; 24: 147–153
   PubMed Web of Science ®Google Scholar
• Devoto P, Flore G, Pira G, Longu G, Gessa G L. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol 2004; 487: 105–111
   PubMed Web of Science ®Google Scholar
• Trendelenburg A U, Starke K, Limberger N. Presynaptic α2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schmiedeberg's Arch Pharmacol 1994a; 350: 473–481
   Google Scholar
• Gobert A, Rivet J-M, Cistarelli L, Melon C, Millan M J. α2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine and serotonin levels in the frontal cortex of freely moving rats. J Neurochem, 1997; 69: 2616–2619
   PubMed Web of Science ®Google Scholar
• Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L, Millan M J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998; 84: 413–429
   PubMed Web of Science ®Google Scholar
• Hertel P, Nomikos G G, Svensson T H. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortes at the nerve terminal level. Eur J Pharmacol 1999; 371: 153–158
   PubMed Web of Science ®Google Scholar
• Kelland M D, Chiodo L A. Serotoninergic modulation of midbrain dopamine systems. The Modulation of Dopaminergic Neurotransmission by other Neurotransmitters, C R Ashby, Jr. CRC Press, New York 1996; 87–122
   Google Scholar
• Gobert A, Rivet J-M, Lejeune F, Newman-Tancredi A, Nicolas J-P, Cistarelli L, Melon C, Millan M J. Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 2000; 36, (in press)
   PubMed Web of Science ®Google Scholar
• Millan M J, Gobert A, Rivet J-M, et al. Mirtazapine enhances frontocortical dopaminergic and corcicolimbic adrenergic, but not serotonergic, transmission by blockade of a2-adrenergic and serotonin2C receptors: A comparison with citalopram. European J Neuroscience 2000; 12: 1079–1095
   PubMed Web of Science ®Google Scholar
• Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Research Bulletin 2004; 63: 23–241
   Web of Science ®Google Scholar
• Littleton J. Receptor regulation as a unitary mechanism for drug tolerance and physical dependence—Not quite as simple as it seemed. Addiction 2001; 96(1)87–101
   PubMed Web of Science ®Google Scholar